These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 8848823

  • 1. Phenobarbital induces the 2-hydroxylation of desipramine.
    Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E.
    Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
    Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E.
    Br J Clin Pharmacol; 1997 Mar; 43(3):315-8. PubMed ID: 9088587
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
    Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E.
    Eur J Clin Pharmacol; 1997 Mar; 51(5):395-8. PubMed ID: 9049581
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.
    Shen HW, Yu AM.
    Drug Metab Lett; 2009 Dec; 3(4):234-41. PubMed ID: 19995332
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E, Birgersson C, von Bahr C, Ericsson O, Mellström B, Steiner E, Sjöqvist F.
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L.
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [Abstract] [Full Text] [Related]

  • 16. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
    Laine K, De Bruyn S, Björklund H, Rouru J, Hänninen J, Scheinin H, Anttila M.
    Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
    [Abstract] [Full Text] [Related]

  • 17. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine.
    Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG.
    J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):798-804. PubMed ID: 8340301
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
    Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA, Spear BB, Katz DA.
    Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.